C domain-selective inhibition of angiotensin-converting enzyme

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 14, Issue 2, 2013, Pages 189-192

  Ehlers, Mario R ^b   Abrie, J Albert ^a   Sturrock, Edward D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; NONHUMAN; PROTEIN HYDROLYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CATALYTIC DOMAIN; DISEASE MODELS, ANIMAL; MICE; MICE, TRANSGENIC; PEPTIDYL-DIPEPTIDASE A;

EID: 84878101763     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313489206     Document Type: Article

References (22)

1. Bernstein KE, Ong FS, Blackwell WL, et al. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev. 2013 ; 65: 1-46
2. Wei L, Clauser E, Alhenc-Gelas F, et al. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem. 1992 ; 267: 13398-13405
3. O'Neill HG, Redelinghuys P, Schwager SL, et al. The role of glycosylation and domain interactions in the thermal stability of human angiotensin- converting enzyme. Biol Chem. 2008 ; 389: 1153-1161
4. Douglas RG, Ehlers MR, Sturrock ED. The anti-fibrotic peptide Ac-Sdkp: Opportunities for ACE inhibitor design. Clin Exp Pharmacol Physiol. :
5. Azizi M, Ezan E, Reny JL, et al. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans. Hypertension. 1999 ; 33: 879-886 (Pubitemid 29140450)
6. Fuchs S, Xiao HD, Cole JM, et al. Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem. 2004 ; 279: 15946-15953 (Pubitemid 38509282)
7. Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol. 2013 ; 10: 125-134
8. Campbell D. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacol Physiol. 1996 ; 3: S125 - S131
9. Nussberger J, Bohlender J. Pharmacotherapy: Optimal blockade of the renin-angiotensin-aldosterone system. Nat Rev Cardiol. 2013 ; 10: 183-184
10. Fuchs S, Xiao HD, Hubert C, et al. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension. 2008 ; 51: 267-274 (Pubitemid 351159938)
11. Woodman ZL, Schwager SL, Redelinghuys P, et al. The N domain of somatic angiotensin-converting enzyme negatively regulates ectodomain shedding and catalytic activity. Biochem J. 2005 ; 389: 739-744 (Pubitemid 41117334)
12. Junot C, Gonzales MF, Ezan E, et al. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J Pharmacol Exp Ther. 2001 ; 297: 606-611 (Pubitemid 32377991)
13. Georgiadis D, Beau F, Czarny B, et al. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: Insights from selective inhibitors. Circ Res. 2003 ; 93: 148-154 (Pubitemid 36919702)
14. van Esch JH, Tom B, Dive V, et al. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension. 2005 ; 45: 120-125 (Pubitemid 40066425)
15. Ocaranza MP, Godoy I, Jalil JE, et al. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension. 2006 ; 48: 572-578 (Pubitemid 44843858)
16. Watermeyer JM, Kroger WL, O'Neill HG, et al. Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochem J. 2010 ; 428: 67-74
17. Douglas RG, Ehlers MRE, Sturrock ED. Vasopeptidase inhibition: Solving the cardiovascular puzzle?. Drugs Fut. 2011 ; 36: 33-43
18. Jullien N, Makritis A, Georgiadis D, et al. Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem. 2009 ; 53: 208-220
19. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010 ; 50: 401-414
20. Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010 ; 375: 1255-1266
21. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet. 2012 ; 380: 1387-1395
22. Maron BA, Leopold JA. Aldosterone receptor antagonists: Effective but often forgotten. Circulation. 2010 ; 121: 934-939